A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma

✍ Scribed by Mace L. Rothenberg; James L. Abbruzzese; Malcolm Moore; Russell K. Portenoy; John M. Robertson; Harold J. Wanebo

• Book ID: 102651579
• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 689 KB
• Volume: 78
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19960801)78:3+<627::aid-cncr7>3.0.co;2-7

✦ Synopsis

BACKGROUND.

Using classical endpoints, such as response rate and survival, as the sole measures of benefit, little progress has been made in the treatment of advanced pancreatic carcinoma in the past 30 years. We challenge the assumption that response rate and survival are the only appropriate endpoints for clinical trials in this disease setting.

METHOD.

A review of the literature and roundtable discussion were undertaken. RESULTS. Using current imaging techniques, it is inherently difficult to distinguish pancreatic tumor from normal pancreas, inflammatory tissue, local fibrosis, and unopacified bowel. As a result, objective tumor measurements are often imprecise, unreliable, and irreproducible. This difficulty may explain the wide variation in response rates reported in clinical trials even when the same therapies are used. Tumor-related symptoms, such as anorexia, weight loss, severe pain (requiring opioid analgesia), and impaired functional status, are prevalent and debilitating characteristics of this disease. Tools that can assess these symptoms in a consistent fashion over time have been developed and have been integrated into clinical trials to evaluate new drugs in this setting. CONCLUSIONS. Systematic assessment of the impact of a new therapy on tumorrelated symptoms may provide a sensitive and accurate way to identi@ useful new treatments for patients with advanced pancreatic carcinoma. Such analyses can be a useful complement to the classical endpoints of response rate and survival.